Last reviewed · How we verify
Acetylcysteine Inhalation
At a glance
| Generic name | Acetylcysteine Inhalation |
|---|---|
| Also known as | Mucomyst |
| Sponsor | VA Greater Los Angeles Healthcare System |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Acetylcysteine Inhalation on Incidence and Time to Develop Ventilator Associated Pneumonia in Critically Ill Mechanically Ventilated Patients (PHASE4)
- The Effect of NAC on Lung Function and CT Mucus Score (PHASE4)
- Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 (PHASE2)
- The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) (PHASE4)
- NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
- N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome (EARLY_PHASE1)
- Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 (PHASE2)
- Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acetylcysteine Inhalation CI brief — competitive landscape report
- Acetylcysteine Inhalation updates RSS · CI watch RSS
- VA Greater Los Angeles Healthcare System portfolio CI